Aurobindo Pharma Limited (AUROPHARMA) Gross Profit 2023–2026

Name: Aurobindo Pharma Limited (AUROPHARMA) gross profit history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Aurobindo Pharma Limited annual gross profit for fiscal 2026 was ₹190.6 billion, an increase of 8.1% from ₹176.4 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

AUROPHARMA Annual Gross Profit

Gross Profit (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Gross Profit	₹190.6B	₹176.4B	₹154.7B	₹127.2B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AUROPHARMA Quarterly Gross Profit

Gross Profit (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Gross Profit	₹54.8B	₹53.2B	₹51.2B	₹45.5B	₹49.5B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Gross Profit at Comparable Companies

4151 Gross Profit — Kyowa Kirin Co., Ltd.
ZYDUSLIFE Gross Profit — Zydus Lifesciences Limited
CIPLA Gross Profit — Cipla Limited
LAURUSLABS Gross Profit — Laurus Labs Limited
DRREDDY Gross Profit — Dr. Reddy's Laboratories Limited
LUPIN Gross Profit — Lupin Limited

More AUROPHARMA metrics: Revenue · Operating Income · Net Income · EPS · Free Cash Flow

All AUROPHARMA financial statements → Interactive AUROPHARMA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.